Identification of the fibroblast growth factor receptor in human vascular endothelial cells.
The fibroblast growth factor (FGF) receptor of human umbilical vein-derived endothelial (HUE) cells has been identified by affinity labeling. It has an apparent molecular weight of 130,000. It binds both basic and acidic FGF, but not with epidermal growth factor, insulin, or transferrin. The lectin concanavalin-A does not inhibit the binding of 125I-bFGF to HUE cell-surface receptors, whereas it inhibits bFGF binding to BHK-21 cell-surface FGF receptor. This suggests that both types of receptors may differ in their degree of glycosylation. In contrast to other cell types, heparin only slightly inhibits the binding of basic FGF to its receptor. Protamine sulfate, which is anti-angiogenic in vivo, and suramin, a drug used in the therapy of trypanosomiasis and onchocerciasis, also inhibit the binding of basic FGF to the receptor.
Neufeld
G
G
Cancer Research Institute, University of California Medical Center, San Francisco 94143.
Gospodarowicz
D
D
D000345:Affinity Labels / Q000378:metabolism; D004730:Endothelium, Vascular / Q000032:analysis*; D004815:Epidermal Growth Factor / Q000378:metabolism; D005346:Fibroblast Growth Factors / Q000378:metabolism; D006031:Glycosylation; D006493:Heparin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D008970:Molecular Weight; D011956:Receptors, Cell Surface / Q000032:analysis*; D017468:Receptors, Fibroblast Growth Factor; D014168:Transferrin / Q000378:metabolism
D000345:Affinity Labels; D007328:Insulin; D011956:Receptors, Cell Surface; D017468:Receptors, Fibroblast Growth Factor; D014168:Transferrin; D005346:Fibroblast Growth Factors; D004815:Epidermal Growth Factor; D006493:Heparin